Philip Wells

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11026042/publications.pdf

Version: 2024-02-01

414034 430442 8,716 32 18 32 citations h-index g-index papers 32 32 32 7949 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.4	4,060
2	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. Thrombosis and Haemostasis, 2000, 83, 416-420.	1.8	1,417
3	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. New England Journal of Medicine, 1999, 340, 901-907.	13.9	1,052
4	Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 349, 631-639.	13.9	728
5	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1143-1163.	0.4	531
6	An Evaluation of <scp>d</scp> -Dimer in the Diagnosis of Pulmonary Embolism. Annals of Internal Medicine, 2006, 144, 812.	2.0	159
7	Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood, 2008, 112, 4432-4436.	0.6	103
8	Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thrombosis and Haemostasis, 2009, 101, 197-200.	1.8	71
9	The diagnosis and treatment of venous thromboembolism. Hematology American Society of Hematology Education Program, 2013, 2013, 457-463.	0.9	60
10	Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Thrombosis and Haemostasis, 2010, 104, 498-503.	1.8	59
11	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.4	58
12	Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thrombosis and Haemostasis, 2010, 104, 760-770.	1.8	51
13	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.4	51
14	Graduated compression stockings to treat acute leg pain associated with proximal DVT. Thrombosis and Haemostasis, 2014, 112, 1137-1141.	1.8	48
15	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 645-650.	1.8	48
16	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	0.6	45
17	DVT Management andÂOutcome Trends, 2001 to 2014. Chest, 2016, 150, 374-383.	0.4	23
18	The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism. Thrombosis and Haemostasis, 2003, 90, 829-834.	1.8	19

#	Article	IF	CITATIONS
19	The Diagnosis of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2012, 38, 691-701.	1.5	18
20	Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. Journal of Medical Economics, 2012, 15, 817-828.	1.0	17
21	Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2017, 5, 18-24.e1.	0.9	15
22	Cast versus functional brace in the rehabilitation of patients treated for an ankle fracture: protocol for the UK study of ankle injury rehabilitation (AIR) multicentre randomised trial. BMJ Open, 2018, 8, e027242.	0.8	15
23	Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry. European Journal of Internal Medicine, 2016, 32, 53-59.	1.0	12
24	Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. Seminars in Thrombosis and Hemostasis, 2018, 44, 341-347.	1.5	12
25	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. American Journal of Medicine, 2017, 130, 482.e1-482.e9.	0.6	9
26	An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears. Trials, 2019, 20, 694.	0.7	9
27	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2017, 117, 2406-2414.	1.8	8
28	Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 195-208.	0.8	7
29	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open, 2018, 02, e1-e7.	0.7	5
30	Scoring Systems for Diagnosis of Acute Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2017, 43, 479-485.	1.5	3
31	Regarding the necessity of an updated meta-analysis on the prognostic value of serum biomarkers in patients with pulmonary embolism. Thrombosis Research, 2019, 176, 8-10.	0.8	2
32	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A crossâ€sectional study using the Canadian Community Health Survey. Cancer Medicine, 2021, 10, 7601-7609.	1.3	1